1. Home
  2. VIAV vs KNSA Comparison

VIAV vs KNSA Comparison

Compare VIAV & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viavi Solutions Inc.

VIAV

Viavi Solutions Inc.

HOLD

Current Price

$26.25

Market Cap

9.0B

Sector

Technology

ML Signal

HOLD

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$87.77

Market Cap

7.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIAV
KNSA
Founded
1923
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
7.7B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
VIAV
KNSA
Price
$26.25
$87.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$62.57
★ $109.43
AVG Volume (30 Days)
★ 5.3M
899.0K
Earning Date
11-04-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 225.00
EPS
N/A
★ 1.14
Revenue
★ $1,518,300,000.00
$677,564,000.00
Revenue This Year
$24.27
$54.96
Revenue Next Year
$13.45
$24.16
P/E Ratio
★ N/A
$84.32
Revenue Growth
40.03
★ 60.09
52 Week Low
$15.51
$37.02
52 Week High
$60.43
$98.48

Technical Indicators

Market Signals
Indicator
VIAV
KNSA
Relative Strength Index (RSI) 38.50 65.74
Support Level $26.56 $72.76
Resistance Level $36.85 N/A
Average True Range (ATR) 2.36 4.78
MACD -0.54 1.43
Stochastic Oscillator 20.16 91.51

Price Performance

Historical Comparison
VIAV
KNSA

About VIAV Viavi Solutions Inc.

Viavi Solutions Inc is a world-wide leader in test and measurement and optical technologies. Its test and measurement, and resilient Position, Navigation and Timing (PNT) solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, it develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets. The company's segments are Network and Service Enablement (NSE); and Optical Security and Performance Products (OSP). Majority of revenue comes from NSE segment. It has presence in Americas, Asia-Pacific, and EMEA. Majority of revenue is from America.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: